LVTX LAVA Therapeutics NV: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
LVTX revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.19M, EPS -0.27
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.64M, EPS -0.32
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.48M, EPS -0.13
- Quarter ended Dec 31, 2024: revenue n/a, net income −$3.88M, EPS -0.15
Recent LVTX insider trades
- Oct 17, 2025: Gilde Healthcare Holding B.V. sold 1,871,370 shares ($2.76M)
- Oct 14, 2025: Gilde Healthcare Holding B.V. sold 275,027 shares ($417K)
- Oct 10, 2025: Gilde Healthcare Holding B.V. sold 126,992 shares ($198K)
- Sep 19, 2025: Versant Venture Capital VI, L.P. sold 2,903,403 shares ($4.06M)
5%+ owners
- Shay Capital LLC: 9.9% (Schedule 13G, filed Sep 26, 2025)
- BML Investment Partners, L.P.: 7.4% (Schedule 13G, filed Mar 3, 2025)
Are insiders buying or selling LVTX?
No open-market insider buys or sells of LAVA Therapeutics NV were reported in the last 12 months.